Under the agreement, the companies will work on process development and manufacturing for MorphoSys’ proprietary MOR208 program and other drug candidates.
MOR208 is a monoclonal anti-CD19 antibody is in development as a treatment for chronic lymphocytic leukemia and potentially other B-cell malignancies.
MorphoSys chief scientific officer Marlies Sproll said adding an additional supplier to their proprietary development set-up will help to prevent any bottlenecks in clinical trial supply in the years ahead.
"Additionally, establishing a commercial manufacturing process with Boehringer Ingelheim early in the development of MOR208 will clearly increase the value of this program," Sproll said.